The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second-line large B-cell lymphoma.
 
Marie José Kersten
Honoraria - Kite, a Gilead company; Novartis; Roche
Consulting or Advisory Role - Kite, a Gilead Company; Miltenyi Biotec (Inst); Novartis; Takeda (Inst)
Research Funding - Kite, a Gilead company (Inst)
Travel, Accommodations, Expenses - Celgene; Kite, a Gilead Company; Novartis; Roche
 
Yao Qiao
Employment - OPEN Health
 
Ruchit Shah
Employment - OPEN Health
 
Caitlyn Solem
Employment - OPEN Health
Stock and Other Ownership Interests - OPEN Health
 
Julia Snider
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Christina Ann To
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
 
Paul Cheng
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Clare Spooner
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Miguel-Angel Perales
Stock and Other Ownership Interests - NexImmune
Honoraria - MorphoSys
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Cidara Therapeutics; Incyte; Kite/Gilead; Medigene; Merck; MolMed; Nektar; NexImmune; Novartis; Omeros; Servier/Pfizer; Vor Biopharma
Research Funding - Incyte (Inst); Kite, a Gilead company (Inst); Miltenyi Biotec (Inst); Nektar (Inst); Novartis (Inst)